Supporting Siblings Through the Allogeneic Hematopoietic Cell Transplant Process: The Perspectives of Minor and Young Adult Siblings of Successful Transplant Recipients  by D'Auria, Jennifer P. et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S211eS232S216compared to participants with lower exercise compliance
during pancytopenic phase after transplant.
Conclusions: By undertaking this study we will ﬁnd out
whether there is preliminary support for the effectiveness of
the currently used in-hospital exercise program for people
who are undergoing HSCT with various levels of pancyto-
penia. We will also determine whether higher compliance
with an exercise program is associated with better functional
outcomes.
Clinical Relevance: Since there are few studies supporting
patient exercising or performing functional activities with
acute pancytopenia, we hope to lay some groundwork in this
area for further research into this and other similar patient
populations.207
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Allogeneic hematopoietic cell transplantation (AHCT)
remains an arduous medical therapy that challenges the
physical and psychological reserves of the family unit at
all stages of the process. Few studies have focused on the
perspectives of healthy siblings regarding the types of
support needed as they journey across the AHCT trajec-
tory. This IRB-approved qualitative study explored the
minor/young adult siblings’ experiences of the AHSCT
experience, speciﬁcally the types of support they would
recommend to other siblings going through this experi-
ence. A retrospective interview approach was used to
capture the perspectives of 12 siblings of successful
pediatric matched sibling donor transplants at our insti-
tution between January 1999 and September 2009. All 12
participants had been HLA tested, with 8 serving as
matched sibling donors. Median age at the time of the
AHCT was 12 years (yrs) (range, 2-23 yrs) and at the time
of the interview was 16 yrs (range, 10-30 yrs). The median
time between donation and the interview was 6 yrs
(range, 2-10 yrs). A grounded theory approach was used
to analyze and interpret transcribed interview data. Semi-
structured private interviews, demographic data, and ﬁeld
notes were the primary sources of data. Seven themes
emerged: (a) being included in the health care “family”,
(b) being involved with the ill sibling, (c) being prepared
for each step of the process, (d) meeting others who have
been through the experience, (e) receiving reassurance
and hope, (f) drawing on the support of parents/family
after the procedure, and (g) talking to others about their
experiences. The stories of these participants supported
that the ill sibling, the family, and the health care team all
play an important role in supporting them across the
transplant trajectory. Interventions must be designed to
focus on the unique physical, emotional and social needs
of siblings to help them make sense of the transplant
process. Age-appropriate educational materials will
provide youth with accurate information as well as a way
to help them ask questions and express emotions. Finally,
providing professional support that extends beyond the
transplant itself is essential for helping them piece
together the meaning of the transplant and related events
for their lives.208
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Pediatric cancer survivorship is a growing subspecialty
however few clinicians focus solely on survivors of hema-
topoietic stem cell transplant (HSCT). There were 100,000
HSCT survivors in the US in 2009 and an estimated 250,000
survivors by 2020 (CIBMTR data). Approximately 80% of
pediatric HSCT patients survive at least two years post
transplant and are expected to become long term survivors.
Post-transplant complications are the third cause of death in
this patient population. The focus of clinical management
then shifts toward decreasing the morbidity of long-term
treatment effects through early detection and intervention.
We piloted a multi-disciplinary pediatric HSCT survivor
clinic. From more than 400 patients transplanted at our
center between 2003 and 2011, 32 patients were seen at one
of 5 long-term follow-up clinic days in July and August 2012.
Eligible patients were at least one year post HSCT and off
immune suppression, and were invited based on availability.
Fourteen patients were male, 18 female. Average age at time
of transplant was 6.7 years (0.1-17 years); average age at time
of survivor clinic was 10.7 years (range 2-20 years). Most
were greater than 4 years post HSCT (range 17-117 months)
and had undergone allogeneic HSCT. The most common late
effects detected were musculoskeletal (59%, primarily
vitamin D deﬁciency and bone mineral loss), and endocrine
(56%). Cardiac late effects were seen in 2 patients and were
not life threatening (1 hypertension and 1 hyperlipidemia).
Pulmonary late effects were seen in 9% of patients, derma-
tologic in 12%, psychological in 18% and 44% were catego-
rized as other, mostly low vaccine titers. No second
malignancies were identiﬁed. School performance concerns
were common (n¼ 40%).
More than 40 referrals were generated to other pediatric
specialists as a result of our evaluation. A comprehensive
cancer summary with speciﬁc recommendations from the
multi-disciplinary team was mailed to each patient and
appropriate medical providers.
Late effects in the growing population of HSCT survivors
are common and, thus create an obligation to screen, apply
early interventions, and refer to appropriate specialists as
part of their post-transplant care.
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Background: With improved survival following pediatric
stem cell transplantation (SCT), long term effects of the
therapy including OP and ON need to be addressed. These
problems are known to occur in adult solid organ trans-
plantation and adult SCT but little is reported in the pediatric
literature. High-risk features associated with diminished
bone density include hypothyroidism, hypogonadism,
